Replies to post #88206 on Biotech Values

[DewDiligence]

I wouldn't buy mdco for the milano drug because they are no further ahead then anyone else that can make it.

Whoever runs the clinical trials to get the drug approved (if anyone does) will get 12 years of data exclusivity under the healthcare bill pending in Congress. Thus, even if another company can make the drug better or cheaper, they’ll have to cut a deal with MDCO unless they have their own set of clinical data.

This could be one of the rare cases where the 12-year data-exclusivity provision in the pending healthcare bill has some consequence.